These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30391234)

  • 41. Drugs on the horizon for diabesity.
    Bailey CJ
    Curr Diab Rep; 2005 Oct; 5(5):353-9. PubMed ID: 16188170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Hodge RJ; Nunez DJ
    Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral antidiabetic drug use and associated health outcomes in cancer patients.
    Tan X; Feng X; Chang J; Higa G; Wang L; Leslie D
    J Clin Pharm Ther; 2016 Oct; 41(5):524-31. PubMed ID: 27453485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FGF21: a novel prospect for the treatment of metabolic diseases.
    Kharitonenkov A; Shanafelt AB
    Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity.
    Karras S; Goulis DG; Mintziori G; Katsiki N; Tzotzas T
    Curr Vasc Pharmacol; 2012 Nov; 10(6):781-91. PubMed ID: 22272906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease.
    Abegg K; Bernasconi L; Hutter M; Whiting L; Pietra C; Giuliano C; Lutz TA; Riediger T
    Diabetes Obes Metab; 2017 Dec; 19(12):1740-1750. PubMed ID: 28544245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs.
    Li J; Lian H
    Arch Pharm Res; 2016 Jun; 39(6):731-46. PubMed ID: 27230777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].
    Sesti G
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):10-6. PubMed ID: 22158422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Development of body weight during antidiabetic treatment].
    Hamann A
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S255-8. PubMed ID: 17139582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
    Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
    J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bi-directional drug-microbiome interactions of anti-diabetics.
    Whang A; Nagpal R; Yadav H
    EBioMedicine; 2019 Jan; 39():591-602. PubMed ID: 30553752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?
    Flatt PR
    Diab Vasc Dis Res; 2007 Jun; 4(2):151-3. PubMed ID: 17654450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
    Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of drugs in the management of diabetes mellitus.
    Das S
    J Indian Med Assoc; 2002 Jul; 100(7):434, 436, 445-7. PubMed ID: 12674168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.
    Mamakou V; Eleftheriadou I; Katsiki N; Makrilakis K; Tsioufis K; Tentolouris N
    Curr Vasc Pharmacol; 2017; 16(1):70-78. PubMed ID: 29032756
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [New therapies for type 2 diabetes mellitus].
    Puig-Domingo M; Pellitero S
    Med Clin (Barc); 2015 Jun; 144(12):560-5. PubMed ID: 25194974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug treatment of obesity.
    Bray GA; Ryan DH
    Psychiatr Clin North Am; 2011 Dec; 34(4):871-80. PubMed ID: 22098810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metformin and body weight.
    Golay A
    Int J Obes (Lond); 2008 Jan; 32(1):61-72. PubMed ID: 17653063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.